Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients with primary biliary cholangitis (PBC), the randomized phase III ...

Research led by the Department of General and Visceral Surgery, Faculty of Medicine, University of Freiburg, Germany has ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid transporter (IBAT), linerixibat. The therapy aims to treat adults with ...

About Volixibat. Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of ...

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking ...

Phase 1 and Phase 2 studies of volixibat demonstrated on-target fecal bile acid excretion, a pharmacodynamic marker of IBAT inhibition, in addition to decreases in LDL cholesterol and increases in ...

However, in 2021, the U.S. Food & Drug Administration approved Mirum Pharmaceuticals’ LIVMARLI® (maralixibat) oral solution, an ileal bile acid transporter (IBAT) inhibitor, to treat the ...

LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for ...

Optimism on Wall Street proved wise and shares of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) rose accordingly to close June 17 at $33, up $7.08, or 27.3%, as the firm disclosed interim results from two ...

Bylvay is an ileal bile acid transporter (IBAT) inhibitor. Although the mechanism by which odevixibat improves pruritus in ALGS is unknown, it may involve inhibition of the IBAT, ...

While bile acids might not be as trendy as gene editing, modulting them has potential for first-in-class therapies for liver diseases. We discussed the future of the area with Ron Cooper ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid transporter (IBAT), linerixibat. The therapy aims to treat adults with ...